Strategic Partnerships Cognoa recently partnered with Catalight to extend post-diagnosis services across a network of over 15,000 practitioners and 25,000 patients annually, presenting an opportunity to offer integrated care pathways, targeted training, and co-branded solutions to Catalight’s ecosystem.

payer Engagement Cognoa has secured payer reimbursement partnerships (Highmark) for Canvas Dx, indicating growing acceptance in insurance coverage; this creates a sales angle to pursue additional insurers and employer health plans seeking validated autism diagnostic tools.

Clinical Leadership With experienced medical leadership additions and an Executive Chair on the board, Cognoa signals a strengthened clinical credibility and potential for deeper hospital and health system collaborations, including hospital networks seeking AI-assisted diagnostic capabilities.

FDA Authorized AI Canvas Dx is FDA-authorized and AI-powered, positioning Cognoa as a trusted vendor for health systems prioritizing regulatory-compliant, objective developmental assessments to improve diagnostic speed and fairness.

Growth via Acquisitions Past acquisitions like MolecuLight and a robust funding base suggest capacity for expanding product lines and entering adjacent pediatric behavioral health markets, offering opportunities for cross-sell of diagnostics, therapy tools, and platform services.